Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed an animal model that allows them to better understand the mechanisms that lead ...

The treatment landscape for multiple myeloma is evolving rapidly, with novel therapies offering renewed hope for patients with relapsed or refractory disease. At this year's American Society of ...

Richardson, MD, gave an overview of the ways that CELMoDs are poised to impact the landscape of multiple myeloma treatment at various stages of disease treatment. At the Miami Cancer Institute’s ...

A new study conducted by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has uncovered a key mechanism behind lenalidomide resistance ...

Tumour reactive T cells identified through transcriptional profiling predict response to multiple myeloma immunotherapy and track treatment activity.

The recent FDA approval of teclistamab (Tecvayli) and daratumumab and hyaluronidase-fihj (Darzelex Faspro) marks a major shift in the treatment paradigm, moving powerful bispecifi ...

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...

Cilta-cel’s mechanism of action allows it to penetrate challenging areas of multiple myeloma, providing deep and durable responses even in high-risk patients, explains Surbhi Sidana, MD, MBBS, ...

C4 Therapeutics (NASDAQ:CCCC) used a presentation at TD Cowen’s 46th Annual Healthcare Conference to outline its near- and mid-term clinical plans, emphasizing its lead multiple myeloma program ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for Blenrep (belantamab mafodotin) for the treatment of relapsed or ...